Several Indian companies, including Larsen & Toubro, Godrej Consumer Products, and Dr Reddy’s Laboratories, are expected to record double-digit growth in their topline and bottomline figures for the March quarter due to healthy execution and strong order books. L&T’s core engineering business is expected to drive the topline with a healthy opening order book. Meanwhile, Revlimid, the cancer drug, is expected to have contributed significantly to growth in Dr Reddy’s US sales.
Vedanta shares slide 10% amid global selloff, fears of growth in metals sector
As exporters from countries such as Vietnam, South Korea, and Japan shift their focus to alternative markets like India and the Middle East, Indian manufacturers
April 7, 2025